- Home
- INVA vs COGT Comparison
INVA vs COGT Comparison
Compare INVA & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- COGT
- Stock Information
- Founded
- INVA 1996
- COGT 2014
- Country
- INVA United States
- COGT United States
- Employees
- INVA N/A
- COGT N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- COGT Health Care
- Exchange
- INVA Nasdaq
- COGT Nasdaq
- Market Cap
- INVA 1.3B
- COGT 1.1B
- IPO Year
- INVA 2004
- COGT 2018
- Fundamental
- Price
- INVA $20.48
- COGT $13.05
- Analyst Decision
- INVA Strong Buy
- COGT Strong Buy
- Analyst Count
- INVA 4
- COGT 11
- Target Price
- INVA $40.25
- COGT $21.20
- AVG Volume (30 Days)
- INVA 790.8K
- COGT 1.3M
- Earning Date
- INVA 11-05-2025
- COGT 08-05-2025
- Dividend Yield
- INVA N/A
- COGT N/A
- EPS Growth
- INVA N/A
- COGT N/A
- EPS
- INVA 0.53
- COGT N/A
- Revenue
- INVA $370,229,000.00
- COGT N/A
- Revenue This Year
- INVA $8.17
- COGT N/A
- Revenue Next Year
- INVA $12.06
- COGT N/A
- P/E Ratio
- INVA $38.42
- COGT N/A
- Revenue Growth
- INVA 12.02
- COGT N/A
- 52 Week Low
- INVA $16.67
- COGT $3.72
- 52 Week High
- INVA $22.00
- COGT $13.50
- Technical
- Relative Strength Index (RSI)
- INVA 56.42
- COGT 66.38
- Support Level
- INVA $19.60
- COGT $11.87
- Resistance Level
- INVA $21.11
- COGT $13.50
- Average True Range (ATR)
- INVA 0.51
- COGT 0.55
- MACD
- INVA 0.05
- COGT 0.05
- Stochastic Oscillator
- INVA 57.89
- COGT 77.16
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.